CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 1,033 enrolled
Drug / intervention
Glipizide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01762046
NCT01762046Phase 1Completed
CompareCT.gov

Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

Massachusetts General Hospital·interventional·Posted Jan 7, 2013·Updated May 6, 2026

In Brief

A Phase 1 clinical trial evaluating Glipizide, Metformin, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 1,033 participants across 3 sites.

Detailed Summary

The SUGAR-MGH investigators are studying the influence of inherited gene variants on the response to two commonly prescribed type 2 diabetes medications, metformin and glipizide. They hypothesize that variants in genes that are associated with type 2 diabetes or related traits may impact the effect of anti-diabetic medications. In addition, physiological responses to an insulin secretagogue or an insulin sensitizer may shed light on the mechanism of action of reported genetic associations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Joslin Diabetes Center, Broad Institute of MIT and Harvard

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 7, 2013
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2015
Study CompletionDec 1, 2025
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 13.5 years ago

Interventions

Glipizidedrug

Metformindrug

Oral Glucose Tolerance Testother